TrialNCT04347239Phase 2Completed
Evaluate the Efficacy & Safety of Leronlimab in Patients With Severe or Critical COVID-19
Study sponsor: CytoDyn, Inc.
Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.
Primary completion2021-10-24Actual
Enrollment · participants484Actual
Source updated2025-10-15Last update listed in the registry record
Version history
Changes to this trial
Pro unlocks the full available history and CSV export. View Pro features
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.